Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Breckenridge Pharmaceutical has launched Mefenamic Acid 250mg Capsules after securing final approval for its abbreviated new drug application (ANDA) from the US Food and Drug Administration (FDA).
Subscribe to our email newsletter
Mefenamic Acid, a nonsteroidal anti-inflammatory drug (NSAID), is one of five approved Breckenridge ANDA products secured from the September 2013 acquisition of certain product assets from Cypress Pharmaceutical.
The company’s Mefenamic Acid Capsules are AB rated to Ponstel, a generic drug marketed by Shionogi Pharma.
Mefenamic acid is indicated for the relief of mild to moderate pain in patients greater than or equal to 14 years of age. The therapy should not exceed one week.
The drug is also indicated to treat primary dysmenorrhea.
Breckenridge is a pharmaceutical marketing, research and development firm that markets a broad range of generic prescription products in many therapeutic categories.
The company markets more than 50 products in a variety of dosage forms and therapeutic categories.